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ucational materials and doing the writing exercise compared to the group receiving
only educational materials.
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OBJECTIVES: To systematically evaluate evidence for the detrimental impact of
long-term therapy with preservative containing topical antiglaucoma treatments
(P) in patients/subjects with glaucoma or ocular hypertension (OH) METHODS:
Systematic review and qualitative synthesis of observational studies comparing
the use of P and preservative-free (PF) treatments in patients/subjects with glau-
coma or OH. RESULTS: Eleven studies met review inclusion criteria. Studies dif-
fered considerably in terms of design (cross sectional, case control, before-after),
treatments recieved (nature and number of anti-glaucoma agents received, differ-
ent nature and/or concentration of preservative) and duration of follow-up. Re-
ported outcomes variously included subjective ocular symptoms, clinical mea-
sures of lacrymal function, sub-clinical markers of ocular surface change or
inflammation and vision related quality of life (QoL). There were no reports of
generic measures of QoL or long-term sequelae, e.g. requirement/ success of glau-
coma-related surgery. The disparity of the studies meant that data were not ame-
nable to statistical pooling. However, qualitatively, the studies provide a body of
evidence which may support an association between the long-term use of P and an
increase in subjective symptoms and clinical and sub clinical signs that are sug-
gestive of damage to the ocular surface. The most common apparent side effect
reported is dry-eye which directly affects vision related QoL. The expression of
symptoms and signs of toxicity appear to be dose dependant and reversible when
exposure to preservative is reduced or discontinued. However, the studies cannot
exclude other contributory factors that may be inherent in topical therapy per se,
e.g., the toxicity of the active agent itself and/or cumulative physical effects of
administration. CONCLUSIONS: The findings suggest that the preservatives in-
cluded in some topical antiglaucoma treatments may at least contribute to ob-
served changes to the ocular surface, impairment of lachrymal function and more
subjective symptoms experienced by patients.
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OBJECTIVES: The assessment of patients’ treatment satisfaction in psoriasis treat-
ment has been undermined by the lack of consensus regarding its conceptualiza-
tion as a measure of treatment success. Our objective is to use structural equation
modeling to test a conceptual model of association between treatment satisfaction,
disease severity and health related quality of life (HRQoL). METHODS: Participants
completed the Treatment Satisfaction Questionnaire for Medication (TSQM) and
the Dermatology Quality of Life Index (DLQI) at the initial study visit (t1) at 3-month
(t2) and at 6-month (t3) follow-up visits. The Psoriasis Area and Severity Index
(PASI) was similarly assessed at t1, t2 and t3. We used structural equation modeling
to simultaneously investigate the association of TSQM with DLQI and PASI.
RESULTS: In separate models, 	TSQM was significantly associated with 	PASI (
-0.21, P  0.01), and 	DLQI (  -0.66, P  0.001), while 	PASI was significantly
associated with 	DLQI ( 0.18, P  0.041). In the simultaneous model, that in-
cluded 	PASI, 	DLQI and 	TSQM, the significant association between PASI and
DLQI diminished ( 0.04, P  0.56). This pattern suggested that 	TSQM mediate
the association between 	PASI and 	DLQI. CONCLUSIONS: Treatment satisfaction
mediates the relationship between disease severity and HRQoL in patients with
moderate-to-severe psoriasis. Using treatment satisfaction as a measure of thera-
peutic success may be important in both clinical trials and in routine management
of psoriasis. Understanding this association may also assist physicians to identify
factors they can modify to improve treatment satisfaction and adherence thus, the
efficiency of psoriasis treatment.
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OBJECTIVES: The aim of the study was to investigate health related quality of life
(HRQoL), disease severity and treatment satisfaction in patients with psoriasis
from three Nordic countries and to analyse how these measures vary across dif-
ferent treatment groups. METHODS: The study is based on data from patient sur-
veys and retrospective chart reviews of psoriasis patients in Denmark, Finland, and
Sweden. Information about HRQoL (EQ-5D and EQ-VAS), Dermatology Life Quality
Index (DLQI), disease severity, and treatment satisfaction was collected from pa-
tient questionnaires. Patient characteristics and type of treatment were collected
from patient records. Patients were categorised according to the most advanced
psoriasis drug treatment received during the last 12 months: emollients, topical
steroids, systemic but not biological drugs, or biological drugs. RESULTS: Six cen-
tres included 404 patients, 64% were men and the mean age was 51 years. The
majority of the patients (76%) had plaque psoriasis. During the last 12 months, 13%
had used only emollients, 33% topical corticosteroids, 28% systemic drugs, and 26%
were treated with biological drugs during part of or during the whole period. Mean
HRQoL according to EQ-5D was 0.75, EQ-VAS 73 and DLQI 6.2. Patients who had not
been treated with biological drugs rated their present condition and disease as
severe or very severe more frequently than those who were treated with biological
drugs during part of or during the whole period. At the time of the survey 70% in the
group treated with biologic drugs indicated that the disease had no or small effect
on their life and they experienced a higher degree of treatment satisfaction than
patients in the other groups. CONCLUSIONS: Biological treatment is associated
with fewer psoriasis related problems and better treatment satisfaction. Patients
treated with only emollients had the lowest treatment satisfaction.
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OBJECTIVES: The aim of this study was to assess the availability of resources for
patients with wet age-related macular degeneration (wAMD) in current clinical
practice. METHODS: Observational, cross-sectional and multicenter study. Eligible
subjects were18 years old, with primary/secondary active subfoveal AMD-related
choroidal neovascularization (CNV) diagnosed 12-18 months prior to inclusion
study. Demographics and resources management (medical visits, treatment time,
number/type of specialists, working tools) data were analyzed. RESULTS: 266 pa-
tients were included (39 centers involved).The median age (Q1-Q3) was 77.0 (71.0-
82.0) years, 55.6% were women. Investigators visited weekly 20.0 (10.0-50.0) pa-
tients with wAMD, 10.0 (10.0-25.0) new patients. At present, 100.0 (45.0-250.0) were
under treatment provided mainly in operating rooms (61.5%). Centers only have
accessible 1.0 (1.0-2.0) operating rooms being available for treatment 2.0 (2.0-5.0)
days per week. In most cases (74.4%) operating rooms were located in different
floors/buildings from ophthalmology services. Waiting time until visit starts was
40.0 (30.0-60.0) minutes and duration of treatment administration was 20.0 (15.0-
50.0) minutes. Time between visit request until medical visit was 20.0 (15.0- 30.0)
days, and from diagnosis to treatment 7.0 (5.0-10.0) days. Staff working in ophthal-
mology departments was mainly: retinologist [3.0 (2.0-5.0) per center], ophthalmol-
ogists [2.5 (1.1-5.0)], fellows [2.2 (1.0-3.0)], nurses [1.5 (1.0-3.0)], optometrists [1.5
(1.0-3.0)] and administrative staff [1.0 (1.0-2.0)]. Clinicians considered insufficient
staff resources for explorations (84.6%) and treatment (46.2%). 30.8% and 20.5% of
investigators reflected lack of diagnostic tools such as optical coherence tomogra-
phy and fluorescein angiography, respectively. CONCLUSIONS: The results of this
study show that more resources for diagnosis and treatment of wAMD disease are
required. These data presented, together with the current policy of reducing the
budget in the Spanish Health System invites reflection on the possible recession
that may suffer the diagnosis and treatment of wAMD and globally our health
system and its implications.
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